cbdMD (YCBD) 10-K 22 Dec 23 2023 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2023	Dec. 11, 2023	Mar. 31, 2023
Document Information [Line Items]
Entity Central Index Key	0001644903
Entity Registrant Name	cbdMD, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Document Type	10-K
Document Annual Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-38299
Entity Incorporation, State or Country Code	NC
Entity Tax Identification Number	47-3414576
Entity Address, Address Line One	8845 Red Oak Blvd
Entity Address, City or Town	Charlotte
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	28217
City Area Code	704
Local Phone Number	445-3060
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 12,717,633.18
Entity Common Stock, Shares Outstanding		2,960,944
Auditor Firm ID	677
Auditor Name	Cherry Bekaert LLP
Auditor Location	Charlotte, North Carolina
Series A Cumulative Convertible Preferred Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	8% Series A Cumulative Convertible Preferred Stock
Trading Symbol	YCBDpA
Security Exchange Name	NYSEAMER
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	common
Trading Symbol	YCBD
Security Exchange Name	NYSEAMER

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Current assets:
Cash and cash equivalents	$ 1,797,860	$ 6,720,234
Accounts receivable	1,216,090	1,447,831
Accounts receivable – discontinued operations	0	1,375
Investment other securities	0	1,000,000
Inventory	4,052,972	4,255,914
Inventory prepaid	182,675	511,459
Prepaid sponsorship	70,061	1,372,845
Prepaid expenses and other current assets	750,383	701,945
Total current assets	8,070,041	16,011,603
Other assets:
Property and equipment, net	716,579	823,310
Operating lease assets	3,350,865	4,477,841
Deposits for facilities	138,708	244,606
Intangible assets	3,219,090	17,834,549
Investment in other securities, noncurrent	700,000	1,400,000
Total other assets	8,125,242	24,780,306
Total assets	16,195,283	40,791,909
Current liabilities:
Accounts payable	1,906,319	2,036,558
Accrued expenses	1,484,441	2,060,762
Operating leases – current portion	1,277,089	1,178,683
Note payable	2,492	9,609
Total current liabilities	4,670,341	5,285,612
Long term liabilities:
Long term liabilities	9	125,491
Operating leases - long term portion	2,403,286	3,680,375
Contingent liability	90,363	276,000
Total long term liabilities	2,493,658	4,081,866
Total liabilities	7,163,999	9,367,478
Commitments and Contingencies (Note 11)
cbdMD, Inc. shareholders' equity:
Preferred stock, authorized 50,000,000 shares, $0.001 par value, 5,000,000 and 500,000 shares issued and outstanding, respectively	5,000	5,000
Common stock, authorized 150,000,000 shares, $0.001 par value, 2,960,573 and 1,348,125 shares issued and outstanding, respectively	2,961	1,348
Additional paid in capital	183,387,095	178,841,646
Accumulated deficit	(174,363,772)	(147,423,563)
Total cbdMD, Inc. shareholders' equity	9,031,284	31,424,431
Total liabilities and shareholders' equity	$ 16,195,283	$ 40,791,909

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Sep. 30, 2023	Sep. 30, 2022
Preferred Stock, Shares Authorized (in shares)	50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001	$ 0.001
Preferred Stock, Shares Issued (in shares)	5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	500,000	500,000
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, issued (in shares)	2,960,573	1,348,125
Common stock, outstanding (in shares)	2,960,573	1,348,125

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Gross Sales	$ 25,053,857	$ 37,122,215
Allowances	(898,495)	(1,718,991)
Total Net Sales	24,155,362	35,403,224
Cost of sales	9,177,703	13,066,639
Gross Profit	14,977,659	22,336,585
Operating expenses	24,246,208	39,647,130
Impairment of goodwill and other intangible assets	13,219,000	60,955,970
Loss from operations	(22,487,549)	(78,266,515)
Realized and unrealized loss on marketable and other securities, including impairments	(700,000)	(33,350)
Gain (loss) on sale of assets	0	88,769
Restructuring expense	0	(602,092)
Decrease of contingent liability	185,638	8,473,999
Other income	0	239,250
Interest income	63,702	16,246
Loss before provision for income taxes	(22,938,209)	(70,083,693)
Benefit (expense) for income taxes	0	0
Net Loss	(22,938,209)	(70,083,693)
Preferred dividends	4,002,000	4,002,005
Net Loss attributable to common shareholders	$ (26,940,209)	$ (74,085,698)
Net Loss per share:
Basic loss per share (in dollars per share)	$ (13.32)	$ (55.8)
Diluted loss per share (in dollars per share)	$ (13.32)	$ (55.8)
Weighted average number of shares Basic: (in shares)	2,022,320	1,327,784
Weighted average number of shares Diluted: (in shares)	2,022,320	1,327,784

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Loss	$ (22,938,209)	$ (70,083,693)
Comprehensive Loss	(22,938,209)	(70,083,693)
Preferred dividends	(4,002,000)	(4,002,005)
Comprehensive Loss available to common shareholders	$ (26,940,209)	$ (74,085,698)

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities:
Net Loss	$ (22,938,209)	$ (70,083,693)
Adjustments to reconcile net (income) loss to net cash used by operating activities:
Stock based compensation	233,666	555,215
Restricted stock expense	109,202	373,610
Write off of prepaid assets due to termination of contractual obligation	884,892	0
Marketing stock amortization	0	907,774
Inventory and materials impairment	175,499	878,142
Intangibles amortization	1,396,459	884,380
Depreciation	404,280	948,962
Impairment of goodwill and other intangible assets	13,219,000	60,955,970
Gain on sale of fixed assets	0	(322,017)
Increase/(Decrease) in contingent liability	(185,638)	(8,473,999)
Realized and unrealized gain of Marketable and other securities	0	33,350
Other-than-temporary impairment on other investments	700,000	0
Amortization of operating lease asset	1,126,976	1,137,119
Changes in operating assets and liabilities:
Accounts receivable	278,482	65,541
Deposits	105,898	284,977
Inventory	27,443	(112,189)
Prepaid inventory	328,784	40,060
Prepaid expenses and other current assets	2,095,323	(289,586)
Accounts payable and accrued expenses	(1,290,141)	(1,812,547)
Operating lease liability	(1,178,683)	(1,151,152)
Deferred revenue / customer deposits	203,341	203,341
Collection on discontinued operations accounts receivable	1,375	9,592
Cash used by operating activities	(4,302,051)	(14,967,150)
Cash flows from investing activities:
Proceeds from sale of other investment securities	1,000,000	0
Purchase of property and equipment	(297,549)	(688,680)
Cash provided (used) by investing activities	702,451	(688,680)
Cash flows from financing activities:
Proceeds from issuance of common stock	2,478,325	0
Note payable	(132,599)	(33,355)
Preferred dividend distribution	(3,668,500)	(4,002,005)
Cash provided by financing activities	(1,322,774)	(4,035,360)
Net increase (decrease) in cash	(4,922,374)	(19,691,190)
Cash and cash equivalents, beginning of year	6,720,234	26,411,424
Cash and cash equivalents, end of year	1,797,860	6,720,234
Cash Payments for:
Interest expense	6,399	2,364
Non-cash financial/investing activities:
Preferred dividends accrued but not paid	667,000	0
Common Stock Earnout Shares [Member]
Non-cash financial/investing activities:
Issuance of Contingent earnout shares:	$ 0	$ 1,086,000

Consolidated Statements of Shar

Consolidated Statements of Shareholders' (Deficit) Equity (Unaudited) - USD ($)	Share-Based Payment Arrangement, Option [Member] Common Stock [Member]	Share-Based Payment Arrangement, Option [Member] Preferred Stock [Member]	Share-Based Payment Arrangement, Option [Member] Additional Paid-in Capital [Member]	Share-Based Payment Arrangement, Option [Member] Retained Earnings [Member]	Share-Based Payment Arrangement, Option [Member]	Commitment Shares [Member] Common Stock [Member]	Commitment Shares [Member] Preferred Stock [Member]	Commitment Shares [Member] Additional Paid-in Capital [Member]	Commitment Shares [Member] Retained Earnings [Member]	Commitment Shares [Member]	Public Offering [Member] Common Stock [Member]	Public Offering [Member] Preferred Stock [Member]	Public Offering [Member] Additional Paid-in Capital [Member]	Public Offering [Member] Retained Earnings [Member]	Public Offering [Member]	Capital Raise [Member] Common Stock [Member]	Capital Raise [Member] Preferred Stock [Member]	Capital Raise [Member] Additional Paid-in Capital [Member]	Capital Raise [Member] Retained Earnings [Member]	Capital Raise [Member]	Common Stock [Member]	Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Sep. 30, 2021																					1,284,075	5,000,000
Balance at Sep. 30, 2021																					$ 1,285	$ 5,000	$ 176,473,767	$ (73,337,865)	$ 103,142,187
Issuance of stock (in shares)																					10,992	0
Issuance of stock																					$ 11	$ 0	404,989	0	405,000
Issuance of options for share based compensation	$ 0	$ 0	$ 505,466	$ 0	$ 505,466
Issuance of restricted stock for share based compensation																					0	0	508,754	0	508,754
Preferred dividend																					0	0	0	(1,000,502)	(1,000,502)
Net Loss																					$ 0	$ 0	0	(19,160,904)	(19,160,904)
Balance (in shares) at Dec. 31, 2021																					1,295,067	5,000,000
Balance at Dec. 31, 2021																					$ 1,296	$ 5,000	177,892,975	(93,499,271)	84,400,000
Balance (in shares) at Sep. 30, 2021																					1,284,075	5,000,000
Balance at Sep. 30, 2021																					$ 1,285	$ 5,000	176,473,767	(73,337,865)	103,142,187
Net Loss																									(70,083,693)
Balance (in shares) at Sep. 30, 2022																					1,348,125	5,000,000
Balance at Sep. 30, 2022																					$ 1,348	$ 5,000	178,841,646	(147,423,563)	31,424,431
Balance (in shares) at Dec. 31, 2021																					1,295,067	5,000,000
Balance at Dec. 31, 2021																					$ 1,296	$ 5,000	177,892,975	(93,499,271)	84,400,000
Issuance of stock (in shares)																					23,873	0
Issuance of stock																					$ 24	$ 0	660,976	0	661,000
Issuance of options for share based compensation	0	0	291,630	0	291,630
Issuance of restricted stock for share based compensation																					0	0	328,515	0	328,515
Preferred dividend																					0	0	0	(1,000,500)	(1,000,500)
Net Loss																					$ 0	$ 0	0	(4,657,215)	(4,657,216)
Balance (in shares) at Mar. 31, 2022																					1,318,940	5,000,000
Balance at Mar. 31, 2022																					$ 1,320	$ 5,000	179,174,096	(99,156,986)	80,023,429
Issuance of stock (in shares)																					13,198	0
Issuance of stock																					$ 13	$ 0	177,987	0	178,000
Issuance of options for share based compensation	0	0	(373,168)	0	(373,168)
Issuance of restricted stock for share based compensation																					0	0	(593,617)	0	(593,617)
Preferred dividend																					0	0	0	(1,000,501)	(1,000,501)
Net Loss																					$ 0	$ 0	0	(31,634,143)	(31,634,143)
Balance (in shares) at Jun. 30, 2022																					1,332,138	5,000,000
Balance at Jun. 30, 2022																					$ 1,333	$ 5,000	178,385,298	(131,791,630)	46,600,000
Issuance of restricted stock for share based compensation																					0	0	129,959	0	129,959
Preferred dividend																					0	0	0	(1,000,501)	(1,000,501)
Net Loss																								(14,631,432)	(14,631,432)
Balance (in shares) at Sep. 30, 2022																					1,348,125	5,000,000
Balance at Sep. 30, 2022																					$ 1,348	$ 5,000	178,841,646	(147,423,563)	31,424,431
Issuance of Common stock (in shares)																					15,987	0
Issuance of Common stock																					$ 15	$ 0	197,986	0	198,001
Issuance of Preferred Stock																					$ 0	$ 0	128,404	0	128,404
Issuance of stock (in shares)																					1,038	0
Issuance of stock																					$ 1	$ 0		0	0
Issuance of Common stock																							(1)
Issuance of options for share based compensation	0	0	79,446	0	79,446
Issuance of restricted stock for share based compensation																					0	0	43,449	0	43,449
Preferred dividend																					0	0	0	(1,000,502)	(1,000,502)
Net Loss																					$ 0	$ 0	0	(3,956,062)	(3,956,062)
Balance (in shares) at Dec. 31, 2022																					1,349,163	5,000,000
Balance at Dec. 31, 2022																					$ 1,349	$ 5,000	178,964,539	(152,380,127)	26,590,761
Balance (in shares) at Sep. 30, 2022																					1,348,125	5,000,000
Balance at Sep. 30, 2022																					$ 1,348	$ 5,000	178,841,646	(147,423,563)	31,424,431
Net Loss																									(22,938,209)
Balance (in shares) at Sep. 30, 2023																					2,960,573	5,000,000
Balance at Sep. 30, 2023																					$ 2,961	$ 5,000	183,387,095	(174,363,772)	9,031,284
Balance (in shares) at Dec. 31, 2022																					1,349,163	5,000,000
Balance at Dec. 31, 2022																					$ 1,349	$ 5,000	178,964,539	(152,380,127)	26,590,761
Issuance of stock (in shares)						2,616	0														8,417	0
Issuance of stock						$ 3	$ 0	$ 29,190	$ 0	$ 29,193											$ 8	$ 0		0	0
Issuance of Common stock																							(8)
Issuance of options for share based compensation	0	0	16,770	0	16,770
Issuance of restricted stock for share based compensation																					0	0	56,801	0	56,801
Preferred dividend																					0	0	0	(1,000,500)	(1,000,500)
Net Loss																					$ 0	$ 0	0	(1,336,802)	(1,336,802)
Issuance of Common stock - A360 (in shares)																					94,277	0
Issuance of Common stock - A360																					$ 94	$ 0	1,399,906	0	1,400,000
Issuance of Common stock - acquisition (in shares)																					2,223	0
Issuance of Common stock - acquisition																					$ 2	$ 0	$ 29,998	$ 0	$ 30,000
Roundup fractional shares resulting from reverse split (in shares)																					1	0	0	0	1
Balance (in shares) at Mar. 31, 2023																					1,456,696	5,000,000
Balance at Mar. 31, 2023																					$ 1,457	$ 5,000	$ 180,497,196	$ (154,717,429)	$ 25,786,224
Issuance of stock (in shares)											0	0				1,350,000	0				9,000	0
Issuance of stock																$ 1,350	$ 0	$ 2,472,730	$ 0	$ 2,474,080	$ 9	$ 0	69,606	0	69,615
Issuance of options for share based compensation	$ 0	$ 0	$ 34,663	$ 0	$ 34,663
Issuance of restricted stock for share based compensation																					0	0	4,845	0	4,845
Preferred dividend																					0	0	0	(1,000,501)	(1,000,501)
Net Loss																					$ 0	$ 0	0	(1,770,404)	(1,770,404)
Issuance of Common stock - A360											$ 0	$ 0	$ 133,200	$ 0	$ 133,200
Fractional share true-up (in shares)																					39,533	0
Fractional share true-up																					$ 39	$ 0	(39)	0	0
Balance (in shares) at Jun. 30, 2023																					2,855,229	5,000,000
Balance at Jun. 30, 2023																					$ 2,855	$ 5,000	183,212,202	(157,488,334)	25,731,723
Issuance of stock (in shares)						105,232	0														112	0
Issuance of stock						$ 105	$ 0	$ 97,338	$ 0	$ 97,443
Issuance of options for share based compensation																					$ 0	$ 0	33,171	0	33,171
Issuance of restricted stock for share based compensation																					0	0	3,996	0	3,996
Preferred dividend																					0	0	0	(1,000,497)	(1,000,497)
Net Loss																					0	0	0	(15,874,941)	(15,874,941)
Issuance of Common stock																0	0	(40,500)	0	(40,500)	0	0	(112)	0	(112)
Maxim transaction expenses																$ 0	$ 0	$ 40,500	$ 0	$ 40,500	$ 0	$ 0	112	0	112
Balance (in shares) at Sep. 30, 2023																					2,960,573	5,000,000
Balance at Sep. 30, 2023																					$ 2,961	$ 5,000	$ 183,387,095	$ (174,363,772)	$ 9,031,284

Note 1 - Organization and Summa

Note 1 - Organization and Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization and Nature of Business cbdMD, Inc. ("cbdMD", "we", "us", “our”, or the “Company”) is a North Carolina corporation formed on March 17, 2015 November 2016 May 1, 2019 September 30. On December 20, 2018 ( two April 2019, five September 30, 2023, five September 30, 2023. The Company owns and operates the nationally recognized CBD (cannabidiol) brands cbdMD, Paw CBD and hempMD. The Company sources cannabinoids, including CBD, which are extracted from non-GMO hemp grown on farms in the United States. CBD and other hemp-derived cannabinoids are natural substances produced from the hemp plant. The products manufactured by and for the Company comply with the 2018 0.3% 2018 not In the third 2019 October 22, 2019, March 15, 2021 Reverse Stock Split On April 12, 2023, one forty April 24, 2023. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI, Paw CBD, Proline Global,and Therapeutics. All material intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The Company's consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying consolidated financial statements include, but are not Cash and Cash Equivalents For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three Accounts Receivable Accounts receivables are stated at cost less an allowance for doubtful accounts, if applicable. Credit is extended to customers after an evaluation of the customer’s financial condition, and generally collateral is not September 30, 2023 September 30, 2022 Merchant Receivable The Company primarily sells its products through the internet and has an arrangement to process customer payments with multiple third 2 5 September 30, 2023 Inventory Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and labor (portions of which we outsource to third Customer Deposits Customer deposits consist of payments received in advance of revenue recognition. Revenue is recognized as revenue recognition criteria are met. Property and Equipment Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are five three may not Fair Value Accounting The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement, not 1 2 3 Level 1 2 1 2 may 3 When the Company records an investment in marketable securities the carrying value is recorded at fair value. Any changes in fair value for marketable securities during a given period will be recorded as an unrealized gain or loss in the consolidated statement of operations. For investment other securities without a readily determinable fair value, the Company may Intangible Assets The Company's intangible assets consist of trademarks and other intellectual property, all of which were previously accounted for in accordance with Accounting Standards Codification (ASC) Topic 350, Intangibles Goodwill and Other not 350 30 35 18. not not 5 December 31, 2021 The Company now accounts for its trademarks in accordance with Accounting Standards Codification (ASC) Topic 360, 20 January 1, 2022 360, may not may not two 360, 360, 5, July 2023, ASC360 July 2023. fourth 2023, fourth 2023. Contingent Liability A significant component of the purchase price consideration for the Company’s acquisition of Cure Based Development includes a fixed number of future shares to be issued as well as a variable number of future shares to be issued based upon the post-acquisition entity reaching certain specified future revenue targets, as further described in Note 6. Revenue Recognition Under ASC 606, Revenue from Contracts with Customers, five 606: Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to a customer. The Company meets that obligation when it has shipped products which have been ordered by the customer. The Company has reviewed its various revenue streams for its other contracts under the five Allocation of Transaction Price In the Company’s current business model, it does not Revenue Recognition The Company records revenue from the sale of its products when risk of loss and title to the product are transferred to the customer, which is upon shipping (and is typically FOB shipping) which is when our performance obligation is met. Net sales are comprised of gross revenues less product returns, trade discounts and customer allowances, which include costs associated with off-invoice mark-downs and other price reductions, as well as trade promotions. These incentive costs are recognized at the later of the date on which the Company recognizes the related revenue or the date on which the Company offers the incentive. The Company currently offers a 60 Disaggregated Revenue The Company’s product revenue is generated primarily through two A description of the Company’s principal revenue generating activities are as follows: - E-commerce sales - consumer products sold through the Company’s online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due prior to the date of shipment; and - Wholesale sales - products sold to the Company’s wholesale customers for subsequent resale. Revenue is recognized when control of the goods is transferred to the customer, in accordance with the terms of the applicable agreement. Payment terms vary and can typically be 30 The following table represents a disaggregation of revenue by sales channel: Fiscal 2023 % of total Fiscal 2022 % of total E-commerce sales $ 19,436,124 80.5 % $ 26,435,203 74.7 % Wholesale sales $ 4,719,238 19.5 % $ 8,968,021 25.3 % Total Net Sales $ 24,155,362 $ 35,403,224 Contract assets represent unbilled receivables and are presented within accounts receivable, net on the consolidated balance sheets. Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the consolidated balance sheets. The Company had no September 30, 2023 2022. Cost of Sales The Company’s cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third Advertising Costs The Company expenses all costs of advertising and related marketing and promotional costs as incurred. The Company incurred $6.0 million and $14.3 million in advertising and marketing and promotional costs included in operating expenses during the years ended September 30, 2023 2022 Income Taxes The Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. As of October 1, 2019, March 15, 2021, The Company accounts for income taxes pursuant to the provisions of the Accounting for Income Taxes 740 not not US GAAP requires management to evaluate tax positions taken by the Company and recognize a tax liability (or asset) if the Company has taken an uncertain tax position that more likely than not not September 30, 2023 2022 no Concentrations Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities. The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 may September 30, 2023 September 30, 2022. Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not September 30, 2023 Stock-Based Compensation The Company accounts for its stock compensation under the ASC 718 10 30, Compensation - Stock Compensation may The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur. Liquidity and Going Concern Considerations The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company experienced a loss of $23 million for the fiscal year ended September 30, 2023. one While the Company is taking strong action, believes in the viability of its strategy and path to profitability, and in its ability to raise additional funds, there can be no may not twelve twelve not may not Earnings (Loss) Per Share The Company uses ASC 260 10, Earnings Per Share On February 16, 2023, one twenty one February 16, 2024. April 12, 2023, one forty April 24, 2023 ( New Accounting Standards The Company will be adopting ASU 2016 13 326 326 October 1, 2023. may

Note 2 - Marketable Securities

Note 2 - Marketable Securities and Investment Other Securities	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	NOTE 2 MARKETABLE SECURITIES AND INVESTMENT OTHER SECURITIES The Company has, from time to time, entered into contracts where a portion of the consideration provided by the customer in exchange for the Company's services was common stock, options or warrants (an equity position). In these situations, upon invoicing the customer for the stock or other instruments, the Company recorded the receivable as accounts receivable other, and used the value of the stock or other instrument upon invoicing to determine the value. If there is insufficient data to support the valuation of the security directly, the Company will value it, and the underlying revenue, on the estimated fair value of the services provided. In determining fair value of marketable securities and investment other securities, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and consider counterparty credit risk in our assessment of fair value. The Company determines the fair value of marketable securities and investment other securities based on assumptions that market participants would use in pricing an asset or liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one ● Level 1 ● Level 2 1 ● Level 3 not For the year ended September 30, 2023 September 30, 2022 In September 2020, January 13, 2021, second June 22, 2022, December 2022, February 10, 2023, June 22, 2022. On April 7, 2022, September 30, 2023 The table below summarizes the assets and liabilities valued at fair value as of September 30, 2023 In Active Markets for Significant Other Significant Identical Assets Observable Unobservable and Liabilities Inputs Inputs (Level 1) (Level 2) (Level 3) Balance at September 30, 2021 $ 33,351 $ - $ (9,856,000 ) Change in value of equities (33,351 ) - - Change in value of contingent liability - - 9,580,000 Additional Investment - - - Balance at September 30, 2022 - - (276,000 ) Change in value of contingent liability - - 185,638 Additional Investment - - - Balance at September 30, 2023 $ - $ - $ (90,362 )

Note 3 - Inventory

Note 3 - Inventory	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	NOTE 3 INVENTORY Inventory at September 30, 2023 2022 September 30, September 30, 2023 2022 Finished Goods $ 2,782,680 $ 3,198,488 Inventory Components 1,397,034 1,213,724 Inventory Reserve (126,742 ) (156,298 ) Inventory prepaid 182,675 511,459 Total Inventory $ 4,235,647 $ 4,767,373 Abnormal amounts of idle facility expense, freight, handling costs, scrap, and wasted material (spoilage) are expensed in the period they are incurred and no September 30, 2023. fourth September 30, 2023

Note 4 - Property and Equipment

Note 4 - Property and Equipment	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 PROPERTY AND EQUIPMENT Major classes of property and equipment at September 30, 2023 2022 September 30, September 30, 2023 2022 Computers, furniture and equipment $ 1,392,776 $ 1,095,228 Manufacturing equipment 284,275 284,275 Leasehold improvements 487,081 487,081 Automobiles 11,087 11,087 2,175,219 1,877,671 Less accumulated depreciation (1,458,640 ) (1,054,361 ) Property and equipment, net $ 716,579 $ 823,310 Depreciation expense related to property and equipment was $404,280 and $948,962 for the year ended September 30, 2023 2022, third

Note 5 - Goodwill and Intangibl

Note 5 - Goodwill and Intangible Assets	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	NOTE 5 GOODWILL AND INTANGIBLE ASSETS Goodwill The Company had goodwill at September 30, 2023 September 2022 FY2022 Intangible Assets On December 20, 2018, not In September 2019, not In July 2021, As of December 31, 2021, 350 30 35 17, December 31, 2021, 350 January 2022. As of July 1, 2023 360. 360 $6,027,000, September 30, 2023 At September 30, 2023 360 360 2023, September 30, 2023. Intangible assets as of September 30, 2023 2022 September 30, September 30, 2023 2022 Trademark related to cbdMD $ 21,585,000 $ 21,585,000 Trademark for HempMD 50,000 50,000 Technology Relief from Royalty related to DirectCBDOnline.com 667,844 667,844 Tradename related to DirectCBDOnline.com 749,567 749,567 Impairment of definite lived intangible assets: (17,504,000 ) (4,285,000 ) Amortization of definite lived intangible assets: (2,329,321 ) (932,862 ) Total $ 3,219,090 $ 17,834,549 Future amortization of intangible assets as of September 30, 2023 For the year ended September 30, 2024 $ 691,368 2025 688,757 2026 660,040 2027 660,040 2028 496,223 Thereafter 22,662 Total future intangibles amortization $ 3,219,090

Note 6 - Contingent Liability

Note 6 - Contingent Liability	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Business Combination Disclosure [Text Block]	NOTE 6 CONTINGENT LIABILITY As consideration for the Mergers, described in Note 1, two five The contractual obligations and earn out provision are accounted for as a contingent liability and fair value is determined using Level 3 may The initial two second The Merger Agreement provides that an additional 338,889 Earnout Shares would be issued as part of the consideration for the Mergers, upon the satisfaction of certain aggregate net revenue criteria by cbdMD within 60 months following the Closing Date as follows, as measured at four 12, 24, 42, 59 Aggregate Net Revenues Shares Issued/ Each $ of Aggregate Net Revenue Ratio $1 - $20,000,000 0.004236111 $20,000,001 - $60,000,000 0.002118056 $60,000,001 - $140,000,000 0.001059028 $140,000,001 - $300,000,000 0.005295139 For clarification purposes, the Aggregate Net Revenues during a Marking Period shall be multiplied by the applicable Shares Issued/Each $ of Aggregate Net Revenue Ratio, minus, the number of shares issued as a result of Aggregate Net Revenues during the prior marking periods. The third third September 30, 2021 December 2021. fourth third December 31, 2021 March 2022. fifth third March 31, 2022 May 2022. sixth third June 30, 2022 August 2022. September 30, 2023, The third 18 January 1, 2021 June 30, 2022 ( March 31, 2021 No. 1 No. 1” third third six third March 31, 2021, no no No. 1 No. 1 not fourth not September 30, 2023 September 30, 2022, The fourth July 1, 2022 November 2023. November 2023, fourth As part of the Twenty Two acquisition in July 2021, one September 30, 2022, September 2022 no In December 2022, four December 31, 2024. September 30, 2023.

Note 7 - Related Party Transact

Note 7 - Related Party Transactions	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 7 RELATED PARTY TRANSACTIONS None.

Note 8 - Shareholders' Equity

Note 8 - Shareholders' Equity	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Equity [Text Block]	NOTE 8 SHAREHOLDERS EQUITY Preferred Stock – The Company is authorized to issue 50,000,000 shares of preferred stock, par value $0.001 per share. In October 2019, 8.0% 8.0% 480 Distinguishing Liabilities from Equity September 30, 2023 September 30, 2022 The total amount of dividends declared were $4,002,000 for the year ended September 30, 2023. September 30, 2022. August 2023 not August September. Common Stock – The Company is authorized to issue 150,000,000 shares of common stock, par value $0.001 per share. There were 2,960,573 and 1,348,125 shares of common stock issued and outstanding at September 30, 2023 2022, Preferred stock transactions: The Company has no September 30, 2023 2022. Common stock transactions: In the year ended September 30, 2023: In September 2023, In July 2023 On May 3, 2023, 45 not On April 24, 2023 In March 2, 2023, 180 March 2, 2023. may 12 April 1, 2023, 75 April 30, 2023. may may In April 2023, March 2023. On February 1, 2023, a360 “a360” a360 A360 September 30,2023. no a360 not December 30, 2023, In January 2023, 2021 In the year ended September 30, 2022: In August 2022, In August 2022, In August 2022, 6. In May 2022, 6. In March 2022 6. In January 2022, six In January 2022, 11. On December 28, 2021, 6. In October 2021, January 1, 2022. Stock option transactions: In the year ended September 30, 2023: In February 2023, five 12 In January 2023, five In December 2022, 3 five December 2024. In the year ended September 30, 2022: In August 2022, five In June 2022, In May 2022, 1, 2, 3 five In April 2022, 6 March 2023. five In April 2022, December 2022. September 30, 2023 no In March 2022, five 12 In January 2022, 9 three June 30, 2022 In October 2021, October 1, 2022. The Company has recorded an expense for these options of $23,025 and $46,050 for the three twelve September 30, 2023. The expected volatility rate was estimated based on comparison to the volatility of a blend of the Company's own stock and a peer group of companies in similar industries. The expected term used was the full term of the contract for the issuances. The risk-free interest rate for periods within the contractual life of the option is based on U.S. Treasury securities. The pre-vesting forfeiture rate of zero 718, may may The following table summarizes the inputs used for the Black-Scholes pricing model on the options issued in the years ended September 30, 2023 2022: 2023 2022 Weighted average exercise price 10.355 -12.6060 $ 44.55 Risk free interest rate 3.93% -4.71 % 2.56% 2.97 % Volatility 106.48% 106.51 % 101.23% 103.98 % Expected term (in years) 2.5 -4 2.5 5.5 Dividend yield None None Warrant transactions: As part of the public underwritten offer discussed earlier in Note 8, 40,500 $2.52 The Company had no twelve September 30, 2022. The following table summarizes the inputs used for the Black-Scholes pricing model on the warrants issued in the year ended September 30, 2023: 2023 Weighted average exercise price $ 2.52 Risk free interest rate 3.37 % Volatility 113.12 % Expected term (in years) 2.75 Dividend yield None

Note 9 - Stock-Based Compensati

Note 9 - Stock-Based Compensation	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	NOTE 9 Equity Compensation Plan – On June 2, 2015, 2015 “2015 2015 2015 first 2015 2016, one September no April 19, 2019, 2015 2015 August 7, 2019 2015 first October 2015 On January 8, 2021, 2021 “2021 March 12, 2021. 2021 2021 2021 2021 October 1 2021 2022, September 30 The Company accounts for stock-based compensation using the provisions of ASC 718. 718 Eligible recipients include employees, officers, directors and consultants who are deemed to have rendered or to be able to render significant services to the Company or its subsidiaries and who are deemed to have contributed or to have the potential to contribute to the success of the Company. Options granted generally have a five ten one three Stock Options: The Company currently has awards outstanding with service conditions and graded-vesting features. We recognize compensation cost on a straight-line basis over the requisite service period. The fair value of each time-based award is estimated on the date of grant using the Black-Scholes option valuation model. Our weighted-average assumptions used in the Black-Scholes valuation model for equity awards with time-based vesting provisions granted during the year. The following table summarizes stock option activity under both plans for the fiscal years ended September 30, 2023 2022 Weighted-average remaining Aggregate Weighted-average contractual term intrinsic value Number of shares exercise price (in years) (in thousands) Outstanding at September 30, 2021 60,101 $ 198.90 5.13 $ - Granted 23,556 43.65 - Exercised - - - Forfeited (28,000 ) 163.35 - Outstanding at September 30, 2022 55,656 151.10 4.55 - Granted 7,233 11.51 - Exercised - - - Forfeited (21,124 ) 88.12 - Outstanding at September 30, 2023 41,765 144.43 3.65 - Exercisable at September 30, 2023 39,542 $ 151.92 3.67 $ - As of September 30, 2023 Restricted Stock Award transactions: In the twelve September 30, 2023: In February 2023, one fourth June 30, 2023, one September 30, 2023, one fourth December 31, 2023, one fourth March 31, 2024. In January 2023, In December 2022, December 2024. In the twelve September 30, 2022: In August 2022, In August 2022, In June 2022, one July 1, 2022 January 1, 2023. In May 2022 In May 2022 In March 2022, one fourth June 30, 2022, one September 30, 2022, one fourth December 31, 2022, one fourth March 31, 2023. In January 2022, six In January 2022, 11. In November 2021, December 2022, 6. January 2022. In October 2021 In October 2021 four

Note 10 - Warrants

Note 10 - Warrants	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Warrants Disclosure [Text Block]	NOTE 10 WARRANTS Transactions involving the Company equity-classified warrants for the fiscal years ended September 30, 2023 2022 Weighted-average remaining Aggregate Weighted-average contractual term intrinsic value Number of shares exercise price (in years) (in thousands) Outstanding at September 30, 2021 14,771 $ 174.60 3.23 $ - Granted - - - Exercised - - - Forfeited (1,567 ) 242.55 - Outstanding at September 30, 2022 13,204 210.45 2.30 - Granted 40,500 2.52 - Exercised - - - Forfeited (3,395 ) 289.08 - Outstanding at September 30, 2023 50,309 37.75 4.07 - Exercisable at September 30, 2023 9,809 $ 183.23 - $ - The following table summarizes outstanding common stock purchase warrants as of September 30, 2023 Weighted-average Number of shares exercise price Expiration Exercisable at $337.5 per share 1,352 $ 337.50 May 2024 Exercisable at $176.06 per share 1,079 176.06 October 2024 Exercisable at $56.25 per share 822 56.25 January 2025 Exercisable at $168.30 per share 3,357 168.30 December 2025 Exercisable at $168.75 per share 3,199 168.75 June 2026 Exercisable at $2.52 per share 40,500 2.52 April 2028 50,309 $ 37.75

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11 COMMITMENTS AND CONTINGENCIES In May 2019, November 4, 2022, November 2022. No one Effective February 2022, February 2025 May 2023, As previously disclosed, during June 2022, June 2022

Note 12 - Note Payable

Note 12 - Note Payable	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Debt Disclosure [Text Block]	NOTE 12 NOTE PAYABLE In July 2019, April 2022, September 30, 2022. January 2020, September 30, 2023.

Note 13 - Leases

Note 13 - Leases	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	NOTE 13 LEASES The Company has lease agreements for its corporate, warehouse and laboratory offices with lease periods expiring between 2024 2026. 842 not Right-of-use lease assets and corresponding lease liabilities are recognized at commencement date based on the present value of lease payments over the expected lease term. Since the interest rate implicit in our lease arrangements is not may In addition to the monthly base amounts in the lease agreements, the Company is required to pay real estate taxes, insurance and common area maintenance expenses during the lease terms. Lease costs on operating leases are recognized on a straight-line basis over the lease term and included as a selling, general and administrative expense in the consolidated statements of operations. Components of operating lease costs are summarized as follows: Year Ended September 30, 2023 Total Operating Lease Costs $ 1,328,497 Supplemental cash flow information related to operating leases is summarized as follows: Year Ended September 30, 2023 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,380,204 As of September 30, 2023 September 30, 2023 For the year ended September 30, 2024 $ 1,421,610 2025 1,159,949 2026 1,372,862 2027 280,565 Total future lease payments 4,234,986 Less interest 274,046 Total lease liabilities $ 3,960,940 Future minimum lease payments (including interest) under non-cancelable operating leases as of September 30, 2022 For the year ended September 30, 2024 $ 1,421,610 2025 1,159,949 2026 1,372,862 2027 280,565 Total future lease payments 4,234,986 Less interest 274,046 Total lease liabilities $ 3,960,940

Note 14 - Loss Per Share

Note 14 - Loss Per Share	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 14 LOSS PER SHARE The following table sets forth the computation of basic and diluted earnings per share for the following periods: Year Ended September 30, September 30, 2023 2022 Basic: Net loss $ (22,938,209 ) $ (70,083,693 ) Preferred dividends paid or accrued 4,002,000 4,002,005 Net income loss attributable to cbdMD Inc. common shareholders (26,940,209 ) (74,085,698 ) Shares used in computing basic earnings per share 2,022,320 1,327,784 Shares used in computing diluted earnings per share 2,022,320 1,327,784 Earnings per share Basic: Basic earnings per share (13.32 ) (55.80 ) Earnings per share Diluted: Diluted earnings per share (13.32 ) (55.80 ) At the year ended September 30, 2023, a360 872 a360

Note 15 - Income Taxes

Note 15 - Income Taxes	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 15 INCOME TAXES The Company generated operating losses for the years ended September 30, 2023 2022 The following table presents the components of the provision for income taxes from continuing operations for the fiscal years ended September 30, 2023 2022 Year Ended September 30, 2023 2022 Current Federal $ - $ - State - - Total current - - Deferred Federal - - State - - Total deferred - - Total provision $ - $ - A reconciliation for the federal statutory income tax rate to the Company’s effective income tax rate is as follows: Year Ended September 30, 2023 2022 Federal statutory income tax rate 21.0 % 21.0 % State income taxes, net of federal benefit 1.4 0.4 Permanent differences (1.5 ) (17.1 ) Contingent derivative expense 0.2 2.5 Change in valuation allowance (21.1 ) (6.8 ) Provision for income taxes 0.0 % 0.0 % Significant components of the Company’s deferred income taxes are shown below: Year Ended September 30, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 14,784,000 $ 12,909,000 ROU - Liability 824,000 1,087,000 Capital loss carryforward 702,000 702,000 Allowance for doubtful accounts 9,000 8,000 Stock compensation 521,000 833,000 Intangibles 105,000 - Investments 180,000 452,000 Accrued expenses 87,000 214,000 Fixed Assets 45,000 40,000 Inventory reserve 28,000 35,000 Capitalized expenses 43,000 48,000 Charitable contributions 39,000 45,000 Total deferred tax assets 17,367,000 16,373,000 Deferred tax liabilities: Prepaid Expenses (107,000 ) (257,000 ) ROU - Assets (750,000 ) (1,002,000 ) Intangibles - (3,426,000 ) Total deferred tax liabilities (857,000 ) (4,685,000 ) Net deferred tax assets 16,510,000 11,688,000 Valuation allowance (16,510,000 ) (11,688,000 ) Net deferred tax liability $ - $ - Net deferred tax liability The Company has established a valuation allowance against net deferred tax assets due to the uncertainty that such assets will be realized. The deferred tax liabilities that result from indefinite life intangibles cannot be offset by deferred tax assets. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not 382, may September 30, 2018, 382 September 30, 2017 2015. September 30, 2018 382. During the year ended September 30, 2020, September 30, 2019. September 30, 2020 382. There have been issuances of stock since 2019 not At September 30, 2023 The Company accounts for its state franchise and minimum taxes as a component of its general and administrative expenses. The Company files income tax returns in the United States, and various state jurisdictions. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. At September 30, 2023 2022, no no The Company has had a valuation allowance against the net deferred tax assets, with the exception of the deferred tax liabilities that result from indefinite-life intangibles ("naked credits"). During the year ended September 30, 2021, zero

Note 16 - Subsequent Events

Note 16 - Subsequent Events	12 Months Ended
	Sep. 30, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 16 SUBSEQUENT EVENTS None.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2023
Accounting Policies [Abstract]
Stockholders' Equity, Policy [Policy Text Block]	Reverse Stock Split On April 12, 2023, one forty April 24, 2023.
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI, Paw CBD, Proline Global,and Therapeutics. All material intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The Company's consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying consolidated financial statements include, but are not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable Accounts receivables are stated at cost less an allowance for doubtful accounts, if applicable. Credit is extended to customers after an evaluation of the customer’s financial condition, and generally collateral is not September 30, 2023 September 30, 2022
Merchant Receivable and Reserve [Policy Text Block]	Merchant Receivable The Company primarily sells its products through the internet and has an arrangement to process customer payments with multiple third 2 5 September 30, 2023
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and labor (portions of which we outsource to third
Deposit Contracts, Policy [Policy Text Block]	Customer Deposits Customer deposits consist of payments received in advance of revenue recognition. Revenue is recognized as revenue recognition criteria are met.
Property, Plant and Equipment, Impairment [Policy Text Block]	Property and Equipment Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are five three may not
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Accounting The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement, not 1 2 3 Level 1 2 1 2 may 3 When the Company records an investment in marketable securities the carrying value is recorded at fair value. Any changes in fair value for marketable securities during a given period will be recorded as an unrealized gain or loss in the consolidated statement of operations. For investment other securities without a readily determinable fair value, the Company may
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets The Company's intangible assets consist of trademarks and other intellectual property, all of which were previously accounted for in accordance with Accounting Standards Codification (ASC) Topic 350, Intangibles Goodwill and Other not 350 30 35 18. not not 5 December 31, 2021 The Company now accounts for its trademarks in accordance with Accounting Standards Codification (ASC) Topic 360, 20 January 1, 2022 360, may not may not two 360, 360, 5, July 2023, ASC360 July 2023. fourth 2023, fourth 2023.
Business Combinations Policy [Policy Text Block]	Contingent Liability A significant component of the purchase price consideration for the Company’s acquisition of Cure Based Development includes a fixed number of future shares to be issued as well as a variable number of future shares to be issued based upon the post-acquisition entity reaching certain specified future revenue targets, as further described in Note 6.
Revenue [Policy Text Block]	Revenue Recognition Under ASC 606, Revenue from Contracts with Customers, five 606: Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to a customer. The Company meets that obligation when it has shipped products which have been ordered by the customer. The Company has reviewed its various revenue streams for its other contracts under the five Allocation of Transaction Price In the Company’s current business model, it does not Revenue Recognition The Company records revenue from the sale of its products when risk of loss and title to the product are transferred to the customer, which is upon shipping (and is typically FOB shipping) which is when our performance obligation is met. Net sales are comprised of gross revenues less product returns, trade discounts and customer allowances, which include costs associated with off-invoice mark-downs and other price reductions, as well as trade promotions. These incentive costs are recognized at the later of the date on which the Company recognizes the related revenue or the date on which the Company offers the incentive. The Company currently offers a 60 Disaggregated Revenue The Company’s product revenue is generated primarily through two A description of the Company’s principal revenue generating activities are as follows: - E-commerce sales - consumer products sold through the Company’s online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due prior to the date of shipment; and - Wholesale sales - products sold to the Company’s wholesale customers for subsequent resale. Revenue is recognized when control of the goods is transferred to the customer, in accordance with the terms of the applicable agreement. Payment terms vary and can typically be 30 The following table represents a disaggregation of revenue by sales channel: Fiscal 2023 % of total Fiscal 2022 % of total E-commerce sales $ 19,436,124 80.5 % $ 26,435,203 74.7 % Wholesale sales $ 4,719,238 19.5 % $ 8,968,021 25.3 % Total Net Sales $ 24,155,362 $ 35,403,224 Contract assets represent unbilled receivables and are presented within accounts receivable, net on the consolidated balance sheets. Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the consolidated balance sheets. The Company had no September 30, 2023 2022.
Cost of Goods and Service [Policy Text Block]	Cost of Sales The Company’s cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third
Advertising Cost [Policy Text Block]	Advertising Costs The Company expenses all costs of advertising and related marketing and promotional costs as incurred. The Company incurred $6.0 million and $14.3 million in advertising and marketing and promotional costs included in operating expenses during the years ended September 30, 2023 2022
Income Tax, Policy [Policy Text Block]	Income Taxes The Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. As of October 1, 2019, March 15, 2021, The Company accounts for income taxes pursuant to the provisions of the Accounting for Income Taxes 740 not not US GAAP requires management to evaluate tax positions taken by the Company and recognize a tax liability (or asset) if the Company has taken an uncertain tax position that more likely than not not September 30, 2023 2022 no
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities. The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 may September 30, 2023 September 30, 2022. Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not September 30, 2023
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company accounts for its stock compensation under the ASC 718 10 30, Compensation - Stock Compensation may The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur.
Liquidity and Going Concern Considerations, Policy [Policy Text Block]	Liquidity and Going Concern Considerations The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company experienced a loss of $23 million for the fiscal year ended September 30, 2023. one While the Company is taking strong action, believes in the viability of its strategy and path to profitability, and in its ability to raise additional funds, there can be no may not twelve twelve not may not
Earnings Per Share, Policy [Policy Text Block]	Earnings (Loss) Per Share The Company uses ASC 260 10, Earnings Per Share On February 16, 2023, one twenty one February 16, 2024. April 12, 2023, one forty April 24, 2023 (
New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Standards The Company will be adopting ASU 2016 13 326 326 October 1, 2023. may

Note 1 - Organization and Sum_2

Note 1 - Organization and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Disaggregation of Revenue [Table Text Block]	Fiscal 2023 % of total Fiscal 2022 % of total E-commerce sales $ 19,436,124 80.5 % $ 26,435,203 74.7 % Wholesale sales $ 4,719,238 19.5 % $ 8,968,021 25.3 % Total Net Sales $ 24,155,362 $ 35,403,224

Note 2 - Marketable Securitie_2

Note 2 - Marketable Securities and Investment Other Securities (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	In Active Markets for Significant Other Significant Identical Assets Observable Unobservable and Liabilities Inputs Inputs (Level 1) (Level 2) (Level 3) Balance at September 30, 2021 $ 33,351 $ - $ (9,856,000 ) Change in value of equities (33,351 ) - - Change in value of contingent liability - - 9,580,000 Additional Investment - - - Balance at September 30, 2022 - - (276,000 ) Change in value of contingent liability - - 185,638 Additional Investment - - - Balance at September 30, 2023 $ - $ - $ (90,362 )

Note 3 - Inventory (Tables)

Note 3 - Inventory (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, September 30, 2023 2022 Finished Goods $ 2,782,680 $ 3,198,488 Inventory Components 1,397,034 1,213,724 Inventory Reserve (126,742 ) (156,298 ) Inventory prepaid 182,675 511,459 Total Inventory $ 4,235,647 $ 4,767,373

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	September 30, September 30, 2023 2022 Computers, furniture and equipment $ 1,392,776 $ 1,095,228 Manufacturing equipment 284,275 284,275 Leasehold improvements 487,081 487,081 Automobiles 11,087 11,087 2,175,219 1,877,671 Less accumulated depreciation (1,458,640 ) (1,054,361 ) Property and equipment, net $ 716,579 $ 823,310

Note 5 - Goodwill and Intangi_2

Note 5 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	September 30, September 30, 2023 2022 Trademark related to cbdMD $ 21,585,000 $ 21,585,000 Trademark for HempMD 50,000 50,000 Technology Relief from Royalty related to DirectCBDOnline.com 667,844 667,844 Tradename related to DirectCBDOnline.com 749,567 749,567 Impairment of definite lived intangible assets: (17,504,000 ) (4,285,000 ) Amortization of definite lived intangible assets: (2,329,321 ) (932,862 ) Total $ 3,219,090 $ 17,834,549
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	For the year ended September 30, 2024 $ 691,368 2025 688,757 2026 660,040 2027 660,040 2028 496,223 Thereafter 22,662 Total future intangibles amortization $ 3,219,090

Note 6 - Contingent Liability (

Note 6 - Contingent Liability (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Aggregate Net Revenues Shares Issued/ Each $ of Aggregate Net Revenue Ratio $1 - $20,000,000 0.004236111 $20,000,001 - $60,000,000 0.002118056 $60,000,001 - $140,000,000 0.001059028 $140,000,001 - $300,000,000 0.005295139

Note 8 - Shareholders' Equity (

Note 8 - Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2023 2022 Weighted average exercise price 10.355 -12.6060 $ 44.55 Risk free interest rate 3.93% -4.71 % 2.56% 2.97 % Volatility 106.48% 106.51 % 101.23% 103.98 % Expected term (in years) 2.5 -4 2.5 5.5 Dividend yield None None 2023 Weighted average exercise price $ 2.52 Risk free interest rate 3.37 % Volatility 113.12 % Expected term (in years) 2.75 Dividend yield None

Note 9 - Stock-Based Compensa_2

Note 9 - Stock-Based Compensation (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted-average remaining Aggregate Weighted-average contractual term intrinsic value Number of shares exercise price (in years) (in thousands) Outstanding at September 30, 2021 60,101 $ 198.90 5.13 $ - Granted 23,556 43.65 - Exercised - - - Forfeited (28,000 ) 163.35 - Outstanding at September 30, 2022 55,656 151.10 4.55 - Granted 7,233 11.51 - Exercised - - - Forfeited (21,124 ) 88.12 - Outstanding at September 30, 2023 41,765 144.43 3.65 - Exercisable at September 30, 2023 39,542 $ 151.92 3.67 $ -

Note 10 - Warrants (Tables)

Note 10 - Warrants (Tables)	12 Months Ended
	Sep. 30, 2023
Common Stock Purchase Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted-average Number of shares exercise price Expiration Exercisable at $337.5 per share 1,352 $ 337.50 May 2024 Exercisable at $176.06 per share 1,079 176.06 October 2024 Exercisable at $56.25 per share 822 56.25 January 2025 Exercisable at $168.30 per share 3,357 168.30 December 2025 Exercisable at $168.75 per share 3,199 168.75 June 2026 Exercisable at $2.52 per share 40,500 2.52 April 2028 50,309 $ 37.75
Equity Classified Warrants [Member]
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Weighted-average remaining Aggregate Weighted-average contractual term intrinsic value Number of shares exercise price (in years) (in thousands) Outstanding at September 30, 2021 14,771 $ 174.60 3.23 $ - Granted - - - Exercised - - - Forfeited (1,567 ) 242.55 - Outstanding at September 30, 2022 13,204 210.45 2.30 - Granted 40,500 2.52 - Exercised - - - Forfeited (3,395 ) 289.08 - Outstanding at September 30, 2023 50,309 37.75 4.07 - Exercisable at September 30, 2023 9,809 $ 183.23 - $ -

Note 13 - Leases (Tables)

Note 13 - Leases (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Lease, Cost [Table Text Block]	Year Ended September 30, 2023 Total Operating Lease Costs $ 1,328,497 Year Ended September 30, 2023 Cash paid for amounts included in the measurement of operating lease liabilities $ 1,380,204
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	For the year ended September 30, 2024 $ 1,421,610 2025 1,159,949 2026 1,372,862 2027 280,565 Total future lease payments 4,234,986 Less interest 274,046 Total lease liabilities $ 3,960,940 For the year ended September 30, 2024 $ 1,421,610 2025 1,159,949 2026 1,372,862 2027 280,565 Total future lease payments 4,234,986 Less interest 274,046 Total lease liabilities $ 3,960,940

Note 14 - Loss Per Share (Table

Note 14 - Loss Per Share (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year Ended September 30, September 30, 2023 2022 Basic: Net loss $ (22,938,209 ) $ (70,083,693 ) Preferred dividends paid or accrued 4,002,000 4,002,005 Net income loss attributable to cbdMD Inc. common shareholders (26,940,209 ) (74,085,698 ) Shares used in computing basic earnings per share 2,022,320 1,327,784 Shares used in computing diluted earnings per share 2,022,320 1,327,784 Earnings per share Basic: Basic earnings per share (13.32 ) (55.80 ) Earnings per share Diluted: Diluted earnings per share (13.32 ) (55.80 )

Note 15 - Income Taxes (Tables)

Note 15 - Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2023
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended September 30, 2023 2022 Current Federal $ - $ - State - - Total current - - Deferred Federal - - State - - Total deferred - - Total provision $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended September 30, 2023 2022 Federal statutory income tax rate 21.0 % 21.0 % State income taxes, net of federal benefit 1.4 0.4 Permanent differences (1.5 ) (17.1 ) Contingent derivative expense 0.2 2.5 Change in valuation allowance (21.1 ) (6.8 ) Provision for income taxes 0.0 % 0.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Year Ended September 30, 2023 2022 Deferred tax assets: Net operating loss carryforwards $ 14,784,000 $ 12,909,000 ROU - Liability 824,000 1,087,000 Capital loss carryforward 702,000 702,000 Allowance for doubtful accounts 9,000 8,000 Stock compensation 521,000 833,000 Intangibles 105,000 - Investments 180,000 452,000 Accrued expenses 87,000 214,000 Fixed Assets 45,000 40,000 Inventory reserve 28,000 35,000 Capitalized expenses 43,000 48,000 Charitable contributions 39,000 45,000 Total deferred tax assets 17,367,000 16,373,000 Deferred tax liabilities: Prepaid Expenses (107,000 ) (257,000 ) ROU - Assets (750,000 ) (1,002,000 ) Intangibles - (3,426,000 ) Total deferred tax liabilities (857,000 ) (4,685,000 ) Net deferred tax assets 16,510,000 11,688,000 Valuation allowance (16,510,000 ) (11,688,000 ) Net deferred tax liability $ - $ -

Note 1 - Organization and Sum_3

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)			1 Months Ended								3 Months Ended		12 Months Ended
	Apr. 12, 2023	Feb. 16, 2023	Nov. 30, 2023 shares	Sep. 30, 2023 USD ($) shares	Sep. 30, 2022 USD ($) shares	Aug. 30, 2022 shares	May 31, 2022 shares	Mar. 31, 2022 shares	Dec. 31, 2021 shares	Apr. 30, 2019 shares	Sep. 30, 2023 USD ($) shares	Dec. 31, 2022 shares	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)
Accounts Receivable, Allowance for Credit Loss				$ 42,180	$ 36,980						$ 42,180		$ 42,180	$ 36,980
Accounts Receivable, after Allowance for Credit Loss, Current				585,345							585,345		585,345
Revenue, Remaining Performance Obligation, Amount				0							0		0
Contract with Customer, Asset, after Allowance for Credit Loss, Total				0							0		0
Marketing and Advertising Expense, Total													6,000,000	14,300,000
Cash, Uninsured Amount				1,163,360	$ 5,752,550						1,163,360		1,163,360	$ 5,752,550
Net Income (Loss) Including Impairment													23,000,000
Equity Method Investment, Other than Temporary Impairment													700,000
Impairment of Intangible Assets (Excluding Goodwill)													13,200,000
Net Income Loss Excluding Investment Impairment Charges				9,100,000							9,100,000		9,100,000
Working Capital				$ 3,400,000							$ 3,400,000		$ 3,400,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers											0
Customer Concentration Risk [Member] | Revenue, Segment Benchmark [Member]
Number of Major Customers											0
cbdMD and directCBDonline Trademarks [Member]
Finite-Lived Intangible Asset, Useful Life (Year)				5 years							5 years		5 years
Trademark Related to Hemp MD [Member]
Finite-Lived Intangible Asset, Useful Life (Year)				10 years							10 years		10 years
Manufacturing Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)				5 years							5 years		5 years
Software [Member]
Property, Plant and Equipment, Useful Life (Year)				3 years							3 years		3 years
Minimum [Member]
MerchantProcessingFee				2.50%							2.50%		2.50%
Maximum [Member]
MerchantProcessingFee				5%							5%		5%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	45
Reverse Stock Split [Member] | Minimum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		20
Reverse Stock Split [Member] | Maximum [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		50
Cure Based Development, Llc [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares										338,889	87,307
Business Acquisition, Equity Interest Issued or Issuable, Vesting Period (Year)					5 years									5 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares) | shares			20,500	87,307		9,101	10,198	9,873	10,372	338,889
Cure Based Development, Llc [Member] | Unregistered Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares) | shares										194,945		48,612
Business Acquisition, Equity Interest Issued or Issuable, Vesting Period (Year)										5 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares) | shares					338,889

Note 1 - Organization and Sum_4

Note 1 - Organization and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Revenues, Total	$ 24,155,362	$ 35,403,224
Sales Channel [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage
Sales Channel, Directly to Consumer [Member]
Revenues, Total	$ 19,436,124	$ 26,435,203
Sales Channel, Directly to Consumer [Member] | Sales Channel [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	80.50%	74.70%
Sales Channel, Through Intermediary [Member]
Revenues, Total	$ 4,719,238	$ 8,968,021
Sales Channel, Through Intermediary [Member] | Sales Channel [Member] | Revenue Benchmark [Member]
Concentration Risk, Percentage	19.50%	25.30%

Note 2 - Marketable Securitie_3

Note 2 - Marketable Securities and Investment Other Securities (Details Textual) - USD ($)				1 Months Ended	12 Months Ended
	Sep. 30, 2023	Jun. 22, 2022	Apr. 07, 2022	Sep. 30, 2020	Sep. 30, 2023	Sep. 30, 2022	Jan. 13, 2021
Marketable Securities, Realized Gain (Loss)					$ 700,000	$ (33,350)
Equity Method Investment, Other than Temporary Impairment					$ 700,000
Steady State, LLC [Member]
Equipment Sold Value			$ 1,800,000
Investments, Total			$ 1,400,000
Equity Method Investment, Other than Temporary Impairment	$ 700,000
Adara Sponser L L C [Member]
Payments to Acquire Additional Interest in Subsidiaries				$ 250,000
Common Stock, Value, Subscriptions							$ 750,000
Proceeds from Equity Method Investment, Distribution, Return of Capital		$ 1,000,000

Note 2 - Marketable Securitie_4

Note 2 - Marketable Securities and Investment Other Securities - Assets Valued at Fair Value (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Fair Value, Inputs, Level 1 [Member]
Balance	$ 0	$ 33,351
Change in value of equities		(33,351)
Change in value of contingent liability	0	0
Additional Investment	0	0
Balance	0	0
Fair Value, Inputs, Level 2 [Member]
Balance	0	0
Change in value of equities		0
Change in value of contingent liability	0	0
Additional Investment	0	0
Balance	0	0
Fair Value, Inputs, Level 3 [Member]
Balance	(276,000)	(9,856,000)
Change in value of equities		0
Change in value of contingent liability	185,638	9,580,000
Additional Investment	0	0
Balance	$ (90,362)	$ (276,000)

Note 3 - Inventory (Details Tex

Note 3 - Inventory (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Inventory Write-down	$ 175,499	$ 878,142

Note 3 - Inventory - Schedule o

Note 3 - Inventory - Schedule of Inventory (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Finished Goods	$ 2,782,680	$ 3,198,488
Inventory Components	1,397,034	1,213,724
Inventory Reserve	(126,742)	(156,298)
Inventory prepaid	182,675	511,459
Total Inventory	$ 4,235,647	$ 4,767,373

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Depreciation, Excluding Lessor Asset under Operating Lease	$ 404,280	$ 948,962

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment - Major Classes of Property and Equipment (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Property and equipment, gross	$ 2,175,219	$ 1,877,671
Less accumulated depreciation	(1,458,640)	(1,054,361)
Property and equipment, net	716,579	823,310
Computers, Furniture, and Equipment [Member]
Property and equipment, gross	1,392,776	1,095,228
Manufacturing Equipment [Member]
Property and equipment, gross	284,275	284,275
Leasehold Improvements [Member]
Property and equipment, gross	487,081	487,081
Automobiles [Member]
Property and equipment, gross	$ 11,087	$ 11,087

Note 5 - Goodwill and Intangi_3

Note 5 - Goodwill and Intangible Assets (Details Textual) - USD ($)		12 Months Ended
	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Jan. 31, 2022	Jul. 31, 2021	Sep. 30, 2019
Goodwill		$ 0	$ 0
Goodwill, Impairment Loss			56.7
Intangible Assets, Net (Excluding Goodwill), Total		3,219,090	17,834,549
Impairment of Intangible Assets, Finite-Lived		13,219,000
Amortization of Intangible Assets		$ 1,396,459	$ 884,380
Trademark Related to Hemp MD [Member]
Intangible Assets, Net (Excluding Goodwill), Total						$ 50,000
Finite-Lived Intangible Asset, Useful Life (Year)		10 years
Trademarks [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	20 years			20 years	10 years
Amortization of Intangible Assets		$ 1,396,459
Developed Technology Rights [Member]
Finite-Lived Intangible Asset, Useful Life (Year)					4 years
Trademark Related to cbdMD [Member]
Impairment of Intangible Assets, Finite-Lived	$ 4,285,000
cbdMD and directCBDonline Trademarks [Member]
Finite-Lived Intangible Asset, Useful Life (Year)		5 years
Impairment of Intangible Assets, Finite-Lived		$ 7,192,000

Note 5 - Goodwill and Intangi_4

Note 5 - Goodwill and Intangible Assets - Schedule of Intangible Assets and Goodwill (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Impairment of definite lived intangible assets:	$ (17,504,000)	$ (4,285,000)
Amortization of definite lived intangible assets:	(2,329,321)	(932,862)
Intangible Assets, Net (Excluding Goodwill), Total	3,219,090	17,834,549
Technology Relief From Royalty Related To Direct C B D Online Com Member
Definite lived intangible assets	667,844	667,844
Tradename Related To Direct C B D Online Com Member
Definite lived intangible assets	749,567	749,567
Trademark Related to cbdMD [Member]
Indefinite lived trademark	21,585,000	21,585,000
Trademark Related to Hemp MD [Member]
Indefinite lived trademark	$ 50,000	$ 50,000

Note 5 - Goodwill and Intangi_5

Note 5 - Goodwill and Intangible Assets - Future Amortization of Intangible Assets (Details)	Sep. 30, 2023 USD ($)
2024	$ 691,368
2025	688,757
2026	660,040
2027	660,040
2028	496,223
Thereafter	22,662
Total future intangibles amortization	$ 3,219,090

Note 6 - Contingent Liability_2

Note 6 - Contingent Liability (Details Textual) - USD ($)		1 Months Ended											3 Months Ended		12 Months Ended
	Dec. 20, 2018	Nov. 30, 2023	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Aug. 30, 2022	May 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Jul. 31, 2021	Apr. 30, 2019	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability															$ (185,638)	$ (8,473,999)
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 90,363		$ 276,000								$ 90,363		90,363	$ 276,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee (in shares)				556
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee (in shares)				556
Employee Stock Options and Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Minimum Consumer Revenue Required				$ 45,000,000
Employee-related Liabilities, Total			$ 0										$ 0		0
Cure Based Development, Llc [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)												338,889	87,307
Business Acquisition, Equity Interest Issued or Issuable, Vesting Period (Year)					5 years											5 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares)		20,500	87,307			9,101	10,198		9,873	10,372		338,889
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares, Expiration (Month)	60 months											60 months
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability							$ 90,792	$ 17,718	$ 41,914	$ 366,841
Business Combination, Contingent Consideration, Liability, Current							$ 178,000	$ 198,000	$ 325,000	$ 405,000
Business Combination, Contingent Consideration, Liability, Noncurrent			$ 90,362		$ 276,000								$ 90,362		$ 90,362	$ 276,000
Business Acquisition, Equity Interest Issued or Issuable, Aggregate Net Revenue Criteria		$ 35,800,000
Cure Based Development, Llc [Member] | Registered Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)												144,445
Cure Based Development, Llc [Member] | Unregistered Common Stock 2 [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)												194,945
Cure Based Development, Llc [Member] | Unregistered Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares (in shares)												194,945		48,612
Business Acquisition, Equity Interest Issued or Issuable, Vesting Period (Year)												5 years
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares)					338,889
Twenty Two Acquisition [Member] | Common Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Additional Earnout Shares (in shares)											4,445
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability																(73,561)
Business Combination, Contingent Consideration, Liability, Noncurrent					$ 416,000						$ 488,561					$ 416,000

Note 6 - Contingent Considerati

Note 6 - Contingent Consideration - Contingent Liability (Details)	12 Months Ended
	Sep. 30, 2023
Earnout Shares for Revenue Between $1 and $20,000,000 [Member]
Business Acquisition, Contingent Consideration, Shares Issued Per Aggregate Net Revenue Ratio	0.004236111
Earnout Shares for Revenue Between $20,000,001 and $60,000,000 [Member]
Business Acquisition, Contingent Consideration, Shares Issued Per Aggregate Net Revenue Ratio	0.002118056
Earnout Shares for Revenue Between $60,000,001 and $140,000,000 [Member]
Business Acquisition, Contingent Consideration, Shares Issued Per Aggregate Net Revenue Ratio	0.001059028
Earnout Shares for Revenue Between $140,000,001 and $300,000,000 [Member]
Business Acquisition, Contingent Consideration, Shares Issued Per Aggregate Net Revenue Ratio	0.005295139

Note 8 - Shareholders' Equity_2

Note 8 - Shareholders' Equity (Details Textual) - USD ($)							1 Months Ended														3 Months Ended								12 Months Ended
	May 03, 2023	Apr. 24, 2023	Mar. 02, 2023	Feb. 02, 2023	Nov. 04, 2022	Dec. 28, 2021	Sep. 30, 2023	Jul. 31, 2023	Apr. 30, 2023	Feb. 28, 2023	Jan. 31, 2023	Dec. 31, 2022	Aug. 31, 2022	Jun. 30, 2022	May 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Jan. 31, 2022	Oct. 31, 2021	Oct. 31, 2019	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022	Aug. 30, 2023	Jun. 01, 2023	Feb. 01, 2023
Preferred Stock, Shares Authorized (in shares)							50,000,000														50,000,000				50,000,000				50,000,000	50,000,000
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.001														$ 0.001				$ 0.001				$ 0.001	$ 0.001
Preferred Stock, Shares Issued (in shares)							5,000,000														5,000,000				5,000,000				5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							500,000														500,000				500,000				500,000	500,000
Accrued Dividends																															$ 667,000
Common Stock, Shares Authorized (in shares)							150,000,000														150,000,000				150,000,000				150,000,000	150,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.001														$ 0.001				$ 0.001				$ 0.001	$ 0.001
Common Stock, Shares, Issued (in shares)							2,960,573														2,960,573				1,348,125				2,960,573	1,348,125
Common Stock, Shares, Outstanding (in shares)							2,960,573														2,960,573				1,348,125				2,960,573	1,348,125
Proceeds from Issuance of Common Stock																													$ 2,478,325	$ 0
Stock Issued During Period, Shares, Reverse Stock Splits (in shares)		39,533
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)																			556
Stock Issued During Period, Value, Restricted Stock Award, Gross																					$ 3,996	$ 4,845	$ 56,801	$ 43,449	$ 129,959	$ (593,617)	$ 328,515	$ 508,754
Stock Issued During Period, Value, Issued for Services																							$ 1,400,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)																													7,233	23,556
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)																													21,124	28,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)																									$ 44.55					$ 44.55
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount							$ 7,858														7,858								$ 7,858
Professional Athlete [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)																		7,112
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)						10,372
Stock Issued During Period, Value, Issued for Services																		$ 336,000
Share-Based Payment Arrangement, Expense					$ 885,000
A New Executive [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)													667
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)													$ 25.56		$ 38
A New Executive [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)															9,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)													5 years		5 years
Share-Based Payment Arrangement, Expense													$ 10,290		$ 176,985
Consultant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)																4,445
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)																5 years
Share-Based Payment Arrangement, Expense																$ 131,300
Share-Based Payment Arrangement, Employee [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)																		667
Stock Issued During Period, Value, Restricted Stock Award, Gross																		$ 29,250
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)											2,334	2,223				2,223		2,889
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value											$ 15,225
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)																$ 45
Share-Based Payment Arrangement, Employee [Member] | Vesting Annually Over Three Years [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												1,667
Share-Based Payment Arrangement, Expense												$ 13,150
Share-Based Payment Arrangement, Employee [Member] | Vest Upon Achieving Certain Revenue Performance [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)												556
Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)											$ 10.53
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)											5 years
Share-Based Payment Arrangement, Expense																										79,500
Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Option [Member] | Vesting Annually Over Three Years [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)												$ 11.25												$ 11.25
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)												5 years
Director [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)													112
Stock Issued During Period, Value, Restricted Stock Award, Gross													$ 2,854
Board of Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)										2,667							2,667
Board of Directors [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)										$ 12.6							$ 36.81										$ 36.81
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)										5 years							5 years
Share-Based Payment Arrangement, Expense										$ 21,120							$ 57,000
Chief Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)																			1,667
Chief Executive Officer [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense																					$ 23,025								$ 46,050
Warrants With Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	40,500
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.52
Twenty Two Capital [Member]
Stock Issued During Period, Shares, Acquisitions (in shares)											2,223
Consultant [Member]
Option Indexed to Issuer's Equity, Strike Price (in dollars per share)																$ 45
Consultant [Member] | Vesting 6 Months From Effective Date [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)																50,000
Consultant [Member] | Vesting Upon Renewal of Consulting Agreement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares (in shares)																2,223
Consultant [Member] | Equity Compensation Plan [Member]
Stock Issued During Period, Shares, Issued for Services (in shares)													2,223
Stock Issued During Period, Value, Issued for Services													$ 41,000
Former Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period (in shares)														16,667
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount														$ 555,286												$ 555,286
Former Executive Officer [Member] | Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Reversal of Expense														$ 604,714
Purchase Agreement [Member] | Keystone [Member]
Stock Issued During Period, Shares, New Issues (in shares)							102,616	2,616
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,350,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.1
Proceeds from Issuance of Common Stock	$ 2,800,000
Proceeds From Issuance of Common Stock, Net	$ 2,500,000
Stock Issued During Period, Value, Issued for Services																						133,200
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	202,500
Advertising Placement Agreement [Member] | a360 Media, LLC [Member]
Shares Issued, Price Per Share (in dollars per share)																																	$ 14.85
Stock Issued During Period, Shares, Issued for Services (in shares)				134,681
Agreement for Advertising Placement, Credit for Media Support and Advertising Placement																						2,000,000
Agreement for Advertising Placement, Unutilized Amount																						$ 514,904
Percentage of Shares Fully Vested																																70%
Percentage of Shares Vest Upon Each Advertising Placement																																15%
Percentage of Shares Vest Provided No Restrictions in Product Categories																																15%
Common Stock Earnout Shares [Member]
Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)													9,101		10,198		9,873
Series A Cumulative Convertible Preferred Stock [Member]
Preferred Stock, Shares Authorized (in shares)																				5,000,000
Preferred Stock, Dividend Rate, Percentage																				8%									8%
Preferred Stock, Shares Issued (in shares)							5,000,000														5,000,000				5,000,000				5,000,000	5,000,000
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							5,000,000														5,000,000				5,000,000				5,000,000	5,000,000
Dividends, Cash, Total																													$ 4,002,000	$ 4,002,005
Commitment Shares [Member] | Keystone [Member]
Stock Issued During Period, Shares, New Issues (in shares)			2,616						8,889
Purchase Commitment, Maximum Shares Commitment (in shares)			281,934
Share Number, Stock Issuable (in shares)			6,104
Number of Shares Registered for Resale (in shares)			281,934

Note 8 - Shareholders' Equity -

Note 8 - Shareholders' Equity - Fair Value Assumptions of Stock Options (Details)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022 $ / shares
Measurement Input, Exercise Price [Member]
Measurement Input	2.52
Measurement Input, Risk Free Interest Rate [Member]
Measurement Input	0.0337
Measurement Input, Price Volatility [Member]
Measurement Input	1.1312
Measurement Input, Expected Term [Member]
Measurement Input	2.75
Share-Based Payment Arrangement, Option [Member]
Weighted average exercise price (in dollars per share)		$ 44.55
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Risk free interest rate		2.56%
Volatility	106.48%	101.23%
Expected term (in years) (Year)		2 years 6 months
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Risk free interest rate		2.97%
Volatility	106.51%	103.98%
Expected term (in years) (Year)		5 years 6 months

Note 9 - Stock-Based Compensa_3

Note 9 - Stock-Based Compensation (Details Textual) - USD ($)

1 Months Ended

3 Months Ended

12 Months Ended

Apr. 19, 2019

Feb. 28, 2023

Jan. 31, 2023

Dec. 31, 2022

Aug. 31, 2022

Jun. 30, 2022

May 31, 2022

Mar. 31, 2022

Jan. 31, 2022

Nov. 30, 2021

Oct. 31, 2021

Sep. 30, 2023

Jun. 30, 2023

Mar. 31, 2023

Dec. 31, 2022

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Dec. 31, 2021

Sep. 30, 2023

Jan. 08, 2021

Jun. 02, 2015

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)

556

Stock Issued During Period, Value, Restricted Stock Award, Gross

$ 3,996

$ 4,845

$ 56,801

$ 43,449

$ 129,959

$ (593,617)

$ 328,515

$ 508,754

Stock Issued During Period, Value, Issued for Services

1,400,000

Stock Issued During Period, Value, New Issues

$ 69,615

$ 0

$ 0

178,000

$ 661,000

$ 405,000

Executive Officer [Member]

Stock Issued During Period, Shares, New Issues (in shares)

2,778

Share-Based Payment Arrangement, Employee [Member]

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)

667

Stock Issued During Period, Value, Restricted Stock Award, Gross

$ 29,250

Director [Member]

Stock Issued During Period, Shares, Restricted Stock Award, Gross (in shares)

112

Stock Issued During Period, Value, Restricted Stock Award, Gross

$ 2,854

Former Executive Officer [Member]

Stock Issued During Period, Shares, New Issues (in shares)

8,889

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Number of Shares (in shares)

11,112

Stock Issued During Period, Value, New Issues

$ 172,000

Professional Athlete [Member]

Stock Issued During Period, Shares, New Issues (in shares)

7,112

Stock Issued During Period, Value, New Issues

$ 336,000

Share-Based Payment Arrangement, Option [Member]

Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount

$ 7,858

$ 7,858

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)

2 years 3 months 18 days

Share-Based Payment Arrangement, Option [Member] | Share-Based Payment Arrangement, Employee [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)

5 years

Share-Based Payment Arrangement, Expense

79,500

Share-Based Payment Arrangement, Option [Member] | Board of Directors [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)

5 years

5 years

Share-Based Payment Arrangement, Expense

$ 21,120

$ 57,000

Share-Based Payment Arrangement, Option [Member] | Former Executive Officer [Member]

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount

555,286

555,286

Contra Expense From Forfeited Share-based Arrangement

$ 604,714

Restricted Stock [Member] | Executive Officer [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

556

Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

112

Stock Issued During Period, Value, New Issues

$ 3,350

Restricted Stock [Member] | Board of Directors [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

448

448

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value

$ 5,660

$ 16,360

Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche One [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage

0.25%

0.25%

Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche Two [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage

0.25%

0.25%

Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche Three [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage

0.25%

0.25%

Restricted Stock [Member] | Board of Directors [Member] | Share-Based Payment Arrangement, Tranche Four [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage

0.25%

0.25%

Restricted Stock [Member] | Former Executive Officer [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)

11,112

Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount

$ 799,572

$ 799,572

Contra Expense From Forfeited Share-based Arrangement

$ 880,428

Restricted Stock Units (RSUs) [Member] | Share-Based Payment Arrangement, Employee [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

3,889

1,112

667

2,667

112

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value

$ 40,950

$ 29,250

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)

556

Share-Based Payment Arrangement, Expense

$ 6,250

Restricted Stock Units (RSUs) [Member] | Vest Based on Certain Performance Hurdles Prior to December 2024 [Member] | Share-Based Payment Arrangement, Employee [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)

556

Maximum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)

10 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)

3 years

Minimum [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)

5 years

Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)

1 year

The 2015 Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)

26,112

Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Shares Authorized, Percentage

1%

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)

45,445

The 2015 Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Shares Authorized, Shares (in shares)

2,223

The 2021 Plan [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)

111,112

Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Shares Authorized, Percentage

1%

The 2021 Plan [Member] | Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Shares Authorized, Shares (in shares)

5,556

Equity Compensation Plan [Member] | Consultant [Member]

Stock Issued During Period, Shares, Issued for Services (in shares)

2,223

Stock Issued During Period, Value, Issued for Services

$ 41,000

Note 9 - Stock Based Compensati

Note 9 - Stock Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Outstanding (in shares)	55,656	60,101
Outstanding, weighted average exercise price (in dollars per share)	$ 151.1	$ 198.9
Granted (in shares)	7,233	23,556
Granted, weighted average exercise price (in dollars per share)	$ 11.51	$ 43.65
Exercised (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)	$ 0	$ 0
Forfeited (in shares)	(21,124)	(28,000)
Forfeited, weighted average exercise price (in dollars per share)	$ 88.12	$ 163.35
Outstanding, weighted average remaining contractual term (Year)	3 years 7 months 24 days	4 years 6 months 18 days
Outstanding (in shares)	41,765	55,656
Outstanding, weighted average exercise price (in dollars per share)	$ 144.43	$ 151.1
Outstanding, weighted average remaining contractual term (Year)	3 years 7 months 24 days	4 years 6 months 18 days
Exercisable (in shares)	39,542
Exercisable, weighted average exercise price (in dollars per share)	$ 151.92
Exercisable at September 30, 2022 (Year)	3 years 8 months 1 day

Note 10 - Warrants - Schedule o

Note 10 - Warrants - Schedule of Equity-Classified Warrants (Details) - $ / shares	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2021
Outstanding, warrant, contractual term (Year)	4 years 25 days
Granted, warrants (in shares)	40,500	0
Granted, warrant, weighted average exercise price (in dollars per share)	$ 2.52	$ 0
Exercised, warrants (in shares)	0	0
Exercised, warrant, weighted average exercise price (in dollars per share)	$ 0	$ 0
Forfeited, warrants (in shares)	3,395	(1,567)
Forfeited, warrant, weighted average exercise price (in dollars per share)	$ 289.08	$ 242.55
Outstanding, warrants (in shares)	50,309
Outstanding, warrant, weighted average exercise price (in dollars per share)	$ 37.75
Exercised, warrants (in shares)	0	0
Forfeited, warrants (in shares)	(3,395)	1,567
Outstanding, warrants (in shares)	50,309
Outstanding, warrant, weighted average exercise price (in dollars per share)	$ 37.75
Class of warrants, exercisable (in shares)	50,309
Exercisable, weighted average exercise price (in dollars per share)	$ 37.75
Warrants to Purchase Common Stock [Member]
Outstanding, warrants (in shares)	13,204	14,771
Outstanding, warrant, weighted average exercise price (in dollars per share)	$ 210.45	$ 174.6
Outstanding, warrant, contractual term (Year)		2 years 3 months 18 days	3 years 2 months 23 days
Outstanding, warrants (in shares)		13,204
Outstanding, warrant, weighted average exercise price (in dollars per share)		$ 210.45
Outstanding, warrants (in shares)		13,204	14,771
Outstanding, warrant, weighted average exercise price (in dollars per share)		$ 210.45	$ 174.6
Class of warrants, exercisable (in shares)	9,809
Exercisable, weighted average exercise price (in dollars per share)	$ 183.23

Note 10 - Warrants - Summary of

Note 10 - Warrants - Summary of Outstanding Common Stock Purchase Warrants (Details)	Sep. 30, 2023 $ / shares shares
Class of warrants, exercisable (in shares) | shares	50,309
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 37.75
Warrants Expiring September 2023 [Member]
Class of warrants, exercisable (in shares) | shares	1,352
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 337.5
Warrants Expiring May 2024 [Member]
Class of warrants, exercisable (in shares) | shares	1,079
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 176.06
Warrants Expiring October 2024 [Member]
Class of warrants, exercisable (in shares) | shares	822
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 56.25
Warrants Expiring January 2025 [Member]
Class of warrants, exercisable (in shares) | shares	3,357
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 168.3
Warrants Expiring April 2028 [Member]
Class of warrants, exercisable (in shares) | shares	3,199
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 168.75
Warrants Expiring December 2025 [Member]
Class of warrants, exercisable (in shares) | shares	40,500
Exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 2.52

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Nov. 04, 2022	Apr. 30, 2022
Professional Athlete Endorsement Agreement [Member]
Other Commitment, Total		$ 1,500,000
Professional Athlete [Member]
Share-Based Payment Arrangement, Expense	$ 885,000

Note 12 - Note Payable (Details

Note 12 - Note Payable (Details Textual) - USD ($)	1 Months Ended
	Jan. 31, 2020	Sep. 30, 2022	Jul. 31, 2019
Loan Arrangement for Line of Equipment, One [Member]
Debt Instrument, Face Amount			$ 249,100
Long-Term Debt, Total		$ 0
Loan Arrangement for Line of Equipment, Two [Member]
Debt Instrument, Face Amount	$ 35,660
Long-Term Debt, Total	$ 3,000
Loan Arrangement for Line of Equipment, Two [Member] | Notes Payable [Member]
Debt Instrument, Term (Month)	48 months
Debt Instrument, Interest Rate, Stated Percentage	6.20%
Debt Instrument, Periodic Payment, Total	$ 841

Note 13 - Leases (Details Textu

Note 13 - Leases (Details Textual)	Sep. 30, 2023
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 11 months 26 days
Operating Lease, Weighted Average Discount Rate, Percent	4.66%

Note 13 - Leases - Operating Le

Note 13 - Leases - Operating Lease Costs and Supplemental Cash Flow Information (Details)	12 Months Ended
	Sep. 30, 2023 USD ($)
Total Operating Lease Costs	$ 1,328,497
Cash paid for amounts included in the measurement of operating lease liabilities	$ 1,380,204

Note 13 - Leases - Future Minim

Note 13 - Leases - Future Minimum Aggregate Lease Payments (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
2024	$ 1,421,610
2025	1,159,949	$ 1,421,610
2026	1,372,862	1,159,949
2027	280,565	1,372,862
Total future lease payments	4,234,986	4,234,986
Less interest	274,046	274,046
Total lease liabilities	3,960,940	3,960,940
2024	1,159,949	1,421,610
2025	1,372,862	1,159,949
2026	280,565	1,372,862
2027		280,565
Total lease liabilities	$ 3,960,940	$ 3,960,940

Note 14 - Loss Per Share (Detai

Note 14 - Loss Per Share (Details Textual)	12 Months Ended
	Sep. 30, 2023 shares
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	93,222
Series A Cumulative Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	185,223
A360 Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	40,404
Commitment Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	872

Note 14 - Loss Per Share - Basi

Note 14 - Loss Per Share - Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended								12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Sep. 30, 2022
Net Loss	$ (15,874,941)	$ (1,770,404)	$ (1,336,802)	$ (3,956,062)	$ (14,631,432)	$ (31,634,143)	$ (4,657,216)	$ (19,160,904)	$ (22,938,209)	$ (70,083,693)
Preferred dividends									4,002,000	4,002,005
Net Loss attributable to common shareholders									$ (26,940,209)	$ (74,085,698)
Shares used in computing basic earnings per share (in shares)									2,022,320	1,327,784
Shares used in computing diluted earnings per share (in shares)									2,022,320	1,327,784
Basic earnings per share (in dollars per share)									$ (13.32)	$ (55.8)
Diluted earnings per share (in dollars per share)									$ (13.32)	$ (55.8)

Note 15 - Income Taxes (Details

Note 15 - Income Taxes (Details Textual) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2018
Operating Loss Carryforwards, Valuation Allowance	$ 65.9	$ 11.4	$ 2.1
Deferred Tax Asset And Related Valuation Allowance		$ 2.7	$ 0.5

Note 15 - Income Taxes - Compon

Note 15 - Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Federal	$ 0	$ 0
State	0	0
Total current	0	0
Federal	0	0
State	0	0
Total deferred	0	0
Total provision	$ 0	$ 0

Note 15 - Income Taxes - Reconc

Note 15 - Income Taxes - Reconciliation of Effective Income Tax Rate (Details)	12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Federal statutory income tax rate	21%	21%
State income taxes, net of federal benefit	1.40%	0.40%
Permanent differences	(1.50%)	(17.10%)
Contingent derivative expense	0.20%	2.50%
Change in valuation allowance	(21.10%)	(6.80%)
Provision for income taxes	0%	0%

Note 15 - Income Taxes - Signif

Note 15 - Income Taxes - Significant Components of Deferred Income Taxes (Details) - USD ($)	Sep. 30, 2023	Sep. 30, 2022
Net operating loss carryforwards	$ 14,784,000	$ 12,909,000
ROU - Liability	824,000	1,087,000
Capital loss carryforward	702,000	702,000
Allowance for doubtful accounts	9,000	8,000
Stock compensation	521,000	833,000
Intangibles	105,000	0
Investments	180,000	452,000
Accrued expenses	87,000	214,000
Fixed Assets	45,000	40,000
Inventory reserve	28,000	35,000
Capitalized expenses	43,000	48,000
Charitable contributions	39,000	45,000
Total deferred tax assets	17,367,000	16,373,000
Prepaid Expenses	(107,000)	(257,000)
ROU - Assets	(750,000)	(1,002,000)
Intangibles	0	(3,426,000)
Total deferred tax liabilities	(857,000)	(4,685,000)
Net deferred tax assets	16,510,000	11,688,000
Valuation allowance	(16,510,000)	(11,688,000)
Net deferred tax liability	$ 0	$ 0